Distinct miRNA profiles are associated with malignant transformation of pancreatic cystic tumors revealing potential biomarkers for clinical use

Expert Review of Molecular Diagnostics

Volumn 13, Issue 4, 2013, Pages 325-329

  Frampton, Adam E ^a   Gall, Tamara Mh ^a   Giovannetti, Elisa ^b   Stebbing, Justin ^c   Castellano, Leandro ^a   Jiao, Long R ^a   Krell, Jonathan ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

diagnostic; intraductal papillary mucinous neoplasm; IPMN; miRNA; pancreatic ductal adenocarcinoma; PDAC

Indexed keywords

MICRORNA; MICRORNA 10A; MICRORNA 146A; MICRORNA 155; MICRORNA 21; MICRORNA 217; MICRORNA 708; UNCLASSIFIED DRUG;

ARTICLE; CANCER SURGERY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; PANCREAS CYST; PANCREAS RESECTION; PROSPECTIVE STUDY;

EID: 84877299762     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.13.18     Document Type: Article

References (28)

1. D'Angelica M, Brennan MF, Suriawinata AA, Klimstra D, Conlon KC. Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. Ann. Surg. 239(3), 400-408 (2004).
2. Shi C, Hruban RH. Intraductal papillary mucinous neoplasm. Hum. Pathol. 43(1), 1-16 (2012).
3. Salvia R, Crippa S, Falconi M, et al. Branch-duct intraductal papillary mucinous neoplasms of the pancreas: to operate or not to operate? Gut 56(8), 1086-1090 (2007).
4. Pang JC, Minter RM, Kwon RS, et al. The role of cytology in the preoperative assessment and management of patients with pancreaticobiliary tract neoplasms. J. Gastrointest. Surg. 17(3), 501-510 (2013).
5. Lubezky N, Loewenstein S, Ben-Haim M, et al. MicroRNA expression signatures in intraductal papillary mucinous neoplasm of the pancreas. Surgery doi:10.1016/j. surg.2012.11.016 (2013) (Epub ahead of print).
6. Mino-Kenudson M, Fernández-del Castillo C, Baba Y, et al. Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. Gut 60(12), 1712-1720 (2011).
7. Izeradjene K, Combs C, Best M, et al. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell 11(3), 229-243 (2007).
8. Pérez-Mancera PA, Guerra C, Barbacid M, Tuveson DA. What we have learned about pancreatic cancer from mouse models. Gastroenterology 142(5), 1079-1092 (2012).
9. Jiao LR, Frampton AE, Jacob J, et al. MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors. PLoS ONE 7(2), e32068 (2012).
10. Frampton AE, Gall TM, Castellano L, Stebbing J, Jiao LR, Krell J. Towards a clinical use of miRNAs in pancreatic cancer biopsies. Expert Rev. Mol. Diagn. 13(1), 31-34 (2013).
11. Habbe N, Koorstra JB, Mendell JT, et al. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol. Ther. 8(4), 340-346 (2009).
12. Caponi S, Funel N, Frampton AE, et al. The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms. Ann. Oncol. 24(3), 734-741 (2013).
13. Szafranska AE, Davison TS, John J, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 26(30), 4442-4452 (2007).
14. Munding JB, Adai AT, Maghnouj A, et al. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma. Int. J. Cancer 131(2), E86-E95 (2012).
15. Jang JS, Jeon HS, Sun Z, et al. Increased miR-708 expression in NSCLC and its association with poor survival in lung adenocarcinoma from never smokers. Clin. Cancer Res. 18(13), 3658-3667 (2012).
16. Saini S, Yamamura S, Majid S, et al. MicroRNA-708 induces apoptosis and suppresses tumorigenicity in renal cancer cells. Cancer Res. 71(19), 6208-6219 (2011).
17. Ryu S, McDonnell K, Choi H, et al. Suppression of miRNA-708 by polycomb group promotes metastases by calciuminduced cell migration. Cancer Cell 23(1), 63-76 (2013).
18. Saini S, Majid S, Shahryari V, et al. miRNA-708 control of CD44(+) prostate cancer-initiating cells. Cancer Res. 72(14), 3618-3630 (2012).
19. Greither T, Grochola L, Udelnow A, Lautenschlager C, Wurl P, Taubert H. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumours associates with poorer survival. Int. J. Cancer 126(1), 73-80 (2009).
20. Wellner U, Schubert J, Burk UC, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol. 11(12), 1487-1495 (2009).
21. Kim S, Lee UJ, Kim MN, et al. MicroRNA miR-199a regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2). J. Biol. Chem. 283(26), 18158-18166 (2008).
22. Hanoun N, Delpu Y, Suriawinata AA, et al. The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis. Clin. Chem. 56(7), 1107-1118 (2010).
23. Delpu Y, Lulka H, Sicard F, et al. The rescue of miR-148a expression in pancreatic cancer: an inappropriate therapeutic tool. PLoS ONE 8(1), e55513 (2013).
24. Zhang Y, Fan KJ, Sun Q, et al. Functional screening for miRNAs targeting Smad4 identified miR-199a as a negative regulator of TGF-β signalling pathway. Nucleic Acids Res. 40(18), 9286-9297 (2012).
25. Jamieson NB, Morran DC, Morton JP, et al. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clin. Cancer Res. 18(2), 534-545 (2012).
26. Papaconstantinou IG, Manta A, Gazouli M, et al. Expression of microRNAs in patients with pancreatic cancer and its prognostic significance. Pancreas 42(1), 67-71 (2013).
27. Laurila EM, Sandström S, Rantanen LM, et al. Both inhibition and enhanced expression of miR-31 lead to reduced migration and invasion of pancreatic cancer cells. Genes Chromosomes Cancer 51(6), 557-568 (2012).
28. Caponi S, Vasile E, Funel N, et al. Adjuvant chemotherapy seems beneficial for invasive intraductal papillary mucinous neoplasms. Eur. J. Surg. Oncol. 39(4), 396-403 (2013).